BioDrugs

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence

Ira Jacobs*, Reginald Ewesuedo, Sadiq Lula, Charles Zacharchuk

*Corresponding author: Ira Jacobs; Pfizer Essential Health, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017-5755, USA.

Email: ira.jacobs@pfizer.com

Supplementary Table S8. Leading 10 identified congresses publishing on biosimilars (2009–2015)

Congress abstract (total records, all years)	Year					
	2007	2011	2012	2013	2014	2015
AAPS-NBC ($n = 13$)	0	0	0	6	1	6
ASCO (n = 11)	0	1	0	2	5	3
ASH (n = 4)	1	0	0	0	3	0
ISPOR $(n = 4)$	0	0	1	0	1	2
SABCS $(n = 4)$	0	0	1	1	2	0
EULAR $(n = 3)$	0	0	1	1	1	0
ESMO (<i>n</i> = 3)	0	0	2	0	1	0
ISoP (<i>n</i> = 3)	0	1	0	2	0	0
ECC (n = 2)	0	0	0	2	0	0
SoT (<i>n</i> = 2)	0	0	0	0	0	2
EHA (<i>n</i> = 2)	0	0	1	0	1	0
CASSS WCBP $(n = 2)$	0	0	0	0	1	1
AACR $(n = 2)$	0	0	0	2	0	0
ESACT (<i>n</i> = 2)	0	0	0	2	0	0
Grand total	1	2	6	18	16	14

AACR American Association for Cancer Research, AAPS-NBC American Association of Pharmaceutical Scientists National Biotechnology Conference, ASCO American Society of Clinical Oncology, ASH American Society of Hematology, CASSS California Separation Science Society, ECC European Cancer Congress, EHA European Hematology Association, ESACT European Society for Animal Cell Technology, ESMO European Society for Medical Oncology, EULAR European League Against Rheumatism, ISOP International Society of Pharmacovigilance, ISPOR International Society for PharmacoEconomics and Outcomes Research, SABCS San Antonio Breast Cancer Symposium, SoT Society of Toxicology, WCBP Well-Characterized Biotechnology Products – Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products.